API
< Back to situations

Monitor this situation.

[SITUATION] · [ACTIVE] · [BUSINESS]

2 clusters · 3 sources · 9 days · First seen · Last updated

South Korean prostate cancer drug developments

Overview

Developments regarding prostate cancer treatments from South Korean pharmaceutical companies have been reported. Peptron received marketing authorization from Mexico’s Federal Commission for Protection against Sanitary Risk (COFEPRIS) for Lupunia (PT105), a monthly injectable for prostate cancer and precocious puberty. This product utilizes Peptron’s SmartDepot drug delivery platform and was approved via an abbreviated pathway after COFEPRIS recognized South Korea’s Ministry of Food and Drug Safety as a reference authority.

Separately, Hyundai Bioscience obtained approval from the Ministry of Food and Drug Safety (MFDS) for the compassionate use of its drug candidate, Penetrium (CP-PCA07). The approval allows a patient in a Phase 1 clinical trial with metastatic castration-resistant prostate cancer to continue using the oral niclosamide based drug in combination with Enzalutamide for an additional six months.

Entities

Seoul National University Hospital · Hyundai Bioscience · Cofepris · Enzalutamide · Penetrium

Timeline

  1. [HEALTH] 3 sources
    Hyundai Bioscience receives approval for prostate cancer drug use

    Hyundai Bioscience received MFDS approval for the compassionate use of its prostate cancer drug candidate, Penetrium, for a patient in a Phase 1 clinical trial.

  2. [BUSINESS] 2 sources
    Peptron receives Mexican approval for long-acting prostate cancer treatment

    Peptron’s long-acting prostate cancer treatment, Lupunia, has received marketing approval in Mexico, marking the first international authorization for its SmartDepot drug delivery technology.

Sources

biotimes.co.kr · healthmedia.co.kr · newstomato.com